Literature DB >> 2139278

Hepatitis B infection in sub-Saharan Africa. The African Regional Study Group.

C F Kiire1.   

Abstract

Hepatitis B virus (HBV) infection and its sequelae are extremely common in sub-Saharan Africa. The overall hepatitis B surface antigen (HBsAg) carrier rate in the general population is 5-20%, which is amongst the highest in the world. Although perinatal infection occurs with an incidence of 1-5%, the predominant form of transition is horizontal among infants and young children; most infections are acquired between 6 months and the pre-school age (5-6 years). Thus, the traditional concept of 'high-risk groups' is of limited importance in Africa and all children should be regarded as being at risk. Hepatitis B-associated hepatocellular carcinoma is probably the most common tumour affecting males in sub-Saharan Africa, with Mozambique having the highest incidence rate of 103.8 per 100,000 males. Cost-benefit analysis shows that, in sub-Saharan Africa, the most effective way of controlling hepatitis B infection is through mass neonatal vaccination programmes integrated within the Expanded Programme on Immunization without prior testing for HBV markers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139278     DOI: 10.1016/0264-410x(90)90229-f

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  HBV Infection Among HIV-Infected Cohort and HIV-Negative Hospital Attendees in South Western Nigeria.

Authors:  Moses Olubusuyi Adewumi; Emmanuel Donbraye; Waidi Folorunso Sule; Olaniran Olarinde
Journal:  Afr J Infect Dis       Date:  2015

2.  Epidemiology of childhood hepatitis B in India: vaccination related issues.

Authors:  L Kant; A J Hall
Journal:  Indian J Pediatr       Date:  1995 Nov-Dec       Impact factor: 1.967

3.  Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain.

Authors:  F Antoñanzas; R Garuz; J Rovira; F Antón; C Trinxet; E Navas; L Salleras
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

Review 4.  Viral hepatitis.

Authors:  G V Gregorio; G Mieli-Vergani; A P Mowat
Journal:  Arch Dis Child       Date:  1994-04       Impact factor: 3.791

5.  Hepatitis B virus infection in general population in Madagascar: evidence for different epidemiological patterns in urban and in rural areas.

Authors:  P Boisier; L Rabarijaona; M Piollet; J F Roux; H G Zeller
Journal:  Epidemiol Infect       Date:  1996-08       Impact factor: 2.451

6.  Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B.

Authors:  Mohamed A Hassan; W Ray Kim; Ruosha Li; Coleman I Smith; Michael W Fried; Richard K Sterling; Marc G Ghany; Abdus S Wahed; Lilia M Ganova-Raeva; Lewis R Roberts; Anna S F Lok
Journal:  Am J Epidemiol       Date:  2017-08-01       Impact factor: 4.897

7.  Seroprevalence of Hepatitis B Infection in Nigeria: A National Survey.

Authors:  Adebola T Olayinka; Akin Oyemakinde; Muhammad S Balogun; Anthonia Ajudua; Patrick Nguku; Moses Aderinola; Abiodun Egwuenu-Oladejo; Simeon W Ajisegiri; Samuel Sha'aibu; Bolanle O P Musa; Saheed Gidado; Abdulsalami Nasidi
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

8.  Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea.

Authors:  Si Hyun Bae; Seung Kew Yoon; Jeong Won Jang; Chang Wook Kim; Soon Woo Nam; Jong Young Choi; Boo Sung Kim; Young Min Park; Seiji Suzuki; Fuminaka Sugauchi; Masashi Mizokami
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

9.  Detection of mutant p53 in hepatocellular cancer from Turkey and its correlation with clinicopathologic parameters.

Authors:  Cem Cengiz; Ulus S Akarca; Erdem Goker; Gul Yuce
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

10.  Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey.

Authors:  Josephine Bwogi; Fiona Braka; Issa Makumbi; Vinod Mishra; Barnabas Bakamutumaho; Miriam Nanyunja; Alex Opio; Robert Downing; Benon Biryahwaho; Rosamund F Lewis
Journal:  Afr Health Sci       Date:  2009-06       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.